Gilead Sciences International Ltd.'s new two-drug fixed-dose HIV therapy Descovy, containing the new tenofovir prodrug tenofovir alafenamide (TAF) and emtricitabine, has received a positive opinion from Europe's top scientific advisory panel, the Committee for Medicinal Products for Human Use (CHMP), the company announced Feb. 26; Descovy is expected to be approved by the European Commission in two to three months.
CHMP Positive On Descovy, A Safer HIV Therapy?
Tenofovir alafenamide-based regimens could drive the growth of the anti-HIV market for next several years.